HMG-CoA reductase inhibitors (statins), inflammation, and endothelial progenitor cells-New mechanistic insights of atherosclerosis

BioFactors

Volumn 40, Issue 3, 2014, Pages 295-302

  Blum, Arnon ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

Atherosclerosis; Endothelial stem cells; Inflammation

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; AUTACOID; BIOLOGICAL MARKER;

ATHEROSCLEROSIS; AUTOIMMUNITY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); ENDOTHELIAL PROGENITOR CELL; EXERCISE; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; THROMBOSIS; VASCULITIS; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PLAQUE, ATHEROSCLEROTIC;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; ENDOTHELIAL PROGENITOR CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; PLAQUE, ATHEROSCLEROTIC; VASCULITIS;

EID: 84902536233     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1157     Document Type: Review

References (100)

1. Hansson, G. K. and Libby, P. (2006) The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6, 508-519.
2. Hansson, G. K., Libby, P., Schonbeck, U., and Yan, Z.Q. (2002) Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91, 281-291.
3. An, G., Wang, H., Tang, R., Yago T., McDaniel J. M., et al. (2008) P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice. Circulation 117, 3227-3337.
4. Sun, J., Sukhova, G. K., Wolters, P. J., Yang M., Kitamoto S. (2007) Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat. Med. 13, 719-724.
5. Bot, I., de Jager, S. C., Zernecke, A., Lindstedt K. A., van Berkel T. J., et al. (2007) Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E deficient mice. Circulation 115, 2516-2525.
6. Serruys, R. W., Garcia-Garcia, H. M., Buszman, P., Erne P., Verheye S., et al. (2008) Effects of the direct lipoprotein associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118, 1172-1182.
7. Croce, K. and Libby, P. (2007) Intertwining of thrombosis and inflammation in atherosclerosis. Curr. Opin. Hematol., 14, 55-61.
8. Libby, P., Ridker, P. M., and Hansson, G. K. (2009) Inflammation in atherosclerosis. From pathophysiology to practice. J. Am. Coll. Cardiol. 54, 2129-2138.
9. Davenport, P. and Tipping, P. G. (2003). The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E deficient mice. Am. J. Pathol. 163, 1117-1125.
10. Binder, C. J., Hartvigsen, K., Chang, M. K., Miller M., Broide D., et al. (2004) IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 114, 427-437.
11. Fredrikson, G. N., Andersson, L., Soderberg, I., Dimayuga P., Chyu K. Y., et al. (2005) Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of the TH2 specific antibody expression. Autoimmunity 38, 171-179.
12. Van Wanrooij, E. J., van Puijvelde, G. H., de Vos, P., Yagita, H., van Berkel, T. J., et al. (2007) Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27, 204-210.
13. Robertson, A. K., Rudling, M., Zhou, X., Gorerlik, L., Flavell, R. A., et al. (2003) Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J. Clin. Invest. 112, 1342-1350.
14. Ait-Oufella, H., Salomon, B. L., Potteaux, S., Robertson A. K., Gourdy P. (2006) Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12, 178-180.
15. Ludewig, B., Freigang, S., Jaggi, M., Kurrer M. O., Pei Y. C., et al. (2009) Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc. Natl. Acad. Sci. USA 97, 12752-12757.
16. Ridker, P. M. (2007) C reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J. Am. Coll. Cardiol. 49, 2129-2138.
17. Ridker, P. M., Morrow, D. A., Rose, L. M., Rifai, N., Cannon, C. P., et al. (2005) Relative efficacy of atrovastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low density lipoprotein cholesterol<70 mg/dl and C reactive protein<2 mg/l: an analysis of the PROVE-IT TIMI 22 trial. J. Am. Coll. Cardiol. 45, 1644-1648.
18. Morrow, D. A., de Lemos, J. A., Sabatine, M. S., Wiviott S. D., Blazing M. A. (2006) Clinical relevance of C reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial. Circulation 114, 281-288.
19. Ridker, P. M., Rifai, N., Clearfield, M., Downs J. R., Weis S. E. (2001) Measurement of C reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344, 1959-1965.
20. Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest J., Gotto A. M. Jr. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207.
21. Boekholdt, S. M., de Winter, R. J., Kastelein, J. J. (2008) Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are anti-inflammatory drugs the next frontier? Circulation 118, 1120-1122.
22. Hansson, G. K. and Nilsson, J. (2008) Introduction: atherosclerosis as inflammation: a controversial concept becomes accepted. J. Int. Med. 263, 462-463.
23. Gordts, S. C., Van Craeyveld, E., Muthuramu, I., Singh, N., Jacobs, F., et al. (2012) Lipid lowering and HDL raising gene transfer increase endothelial progenitor cells, enhance myocardial vascularity, and improve diastolic function. PLoS One 7, e46849.
24. Van Craeyveld, E., Jacobs, F., Gordts, S. C., De Geest, B. (2012) Low-density lipoprotein receptor gene transfer in hypercholesterolemic mice improves cardiac function after myocardial infarction. Gene Ther. 19, 860-871.
25. Tsunekawa, T., Hayashi, T., Kano, H., Sumi D., Matsui-Hirai H. (2001) Cervistatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104, 376-379.
26. Laheta, V., Goicoechea, M., Garcia de Vinuesa, S., de Vinuesa S. G., Praga M. (2007) Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr. Med. Chem. 14, 243-248.
27. Dichtl, W., Dulak, J., Frick, M., Alber H. F., Schwarzacher S. P., et al. (2003) HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 23, 58-63.
28. Di Angelantonio, E., Gao P., Pennells L., Kaptoge S., Caslake M., et al. (2012) Lipid-related markers and cardiovascular disease prediction. JAMA 307:2499-2506.
29. White, H., Held, C., Stewart, R., Watson D., Harrington R., et al. (2010) Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am. Heart J. 160, 655-661.
30. Ridker, P. M., Thuren, T., Zalewski, A., and Libby, P. (2011) Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory thrombosis outcomes study (CANTOS). Am. Heart J. 162, 597-605.
31. Hakamada-Taguchi, R., Uehara, Y., Kuribayashi, K., Numabe A., Saito K. (2003) Inhibition of hydroxymethylglutaryl-coenzyme A reductase reduces Th1 development and promotes Th2 development. Circ. Res. 93, 948-956.
32. Laufs, U., La Fata, V., Plutzky, J., Liao, K. L. (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97, 1129-1135.
33. Kuwahara, N., Sasaki, S., Kobara, M., Nakata T., Tatsumi T., (2008) HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis. Int. J. Cardiol. 123, 84-90.
34. Undas, A., Brummel, K. E., Musial, J., Mann, K. G., Szczeklik, A. (2001) Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 103, 2248-2253.
35. Cortellaro, M., Cofranceso, E., Arbustini, E., Rossi F., Negri A., et al. (2002) Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb. Haemost. 88:41-47.
36. Kinlay, S., Libby, P., and Ganz, P. (2001) Endothelial function and coronary artery disease. Curr. Opin. Lipidol. 12, 383-389.
37. Luscher, T. F. and Barton, M. (1997) Biology of the endothelium. Clin. Cardiol. 20(suppl II):II-3-II-10.
38. Drexler, H. (1998) Factors involved in the maintenance of endothelial function. Am. J. Cardiol. 82:3S-4S.
39. Sowers, J. R. (2002) Hypertension, angiotensin II, and oxidative stress. N. Engl. J. Med. 346, 1999-2001.
40. Laufs, U., La Fata, V., Plutzky, J., Liao J. K. (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97, 1129-1135.
41. Laufs, U. and Liao, J. K. (2000) Targeting Rho in cardiovascular disease. Circ. Res. 87, 526-528.
42. Romano, M., Mezzetti, A., Marulli, C., Ciabattoni G., Febo F. (2000) Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J. Investig. Med. 48, 183-189.
43. Rubanayi, G. M. (1993) The role of endothelium in cardiovascular homeostasis and diseases. J. Cardiovasc. Oharmacol. 22(Suppl4):S1-14.
44. Celermajer, D. S., Sorensen, K. E., Gooch, V. M., Spiegelhalter D. J., Miller O. I. (1992) Non invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340, 1111-1115.
45. Anderson, T. J., Uehata, A., Gerhard, M. D., Meredith I. T., Knab S. et al. (1995) Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26, 1235-1241.
46. Vogel, R. A., Corretti, M. C., and Gellman, J. (1998) Cholesterol, cholesterol lowering, and endothelial function. Prog. Cardiovascul. Dis. 41, 117-136.
47. Dogra, G., Rich, L., Stanton, K., and Watts, G. F. (2001) Endothelium-dependent and independent vasodilation studies at normoglycemia in type 1 diabetes mellitus with and without microalbuminuria. Diabetologia 44, 593-601.
48. Neunteufl, T., Neher, S., Katzenschlager, R., Wölfl G., Kostner K., et al. (2000) Late prognostic value of flow mediated dilation in the brachial artery of patients with chest pain. Am. J. Cardiol. 86, 207-210.
49. Dogra, G. K., Watts, G. F., Herrmann, S., Thomas, M. A. B., and Irish, A. B. (2002) Statin therapy improves brachial artery endothelial function in nephritic syndrome. Kid. Int. 62, 550-557.
50. John, S., Schneider, M. P., Delles, C., Jacobi, J., and Schmieder, R. E. (2005) Lipid independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am. Heart J. 149: 473-475.
51. Davignon, J. and Ganz, P. (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109(suppl III): III-27-III-32.
52. Beishuizen, E. D., Tamsma, J. T., Jukema, J. W., van de Ree M. .A, van der Vijver J. C., et al. (2005) The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care 28:1668-1674.
53. Romano, M., Mezzetti, A., Marulli, C., Ciabattoni G., Febo F. (2000) Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J. Incest. Med. 48, 183-189.
54. Feron, O., Dessy, C., Desager, J. P., Balligand J. L. (2001) Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103, 113-118.
55. Wassmann, S., Laufs, U., Baumer, A. T., Müller K., Ahlbory K. (2001) HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37, 1450-1457.
56. Davignon, J. (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109: III-39-III-43.
57. Kureishi, Y., Luo, Z. Y., Dhiojima, I., Bialik A., Fulton D. (2000) The HMG-CoA redcuctase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6, 1004-1010.
58. Heart Protection Study Collaborative Group. (2002) MRC/BHF heart protection study of antioxidant vitamin supplementation in 20536 high risk individuals: a randomized placebo-controlled trial. Lancet 360, 23-33.
59. Witztum, J. L. and Steinberg, D. (2001) The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc. Med. 11: 93-102.
60. Suzumura, K., Yasuhara, M., Tanaka, K., Suzuki T. (1999) Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor on oxidative modification of human low density lipoprotein in vitro. Biochem. Pharmacol. 57, 697-703.
61. Aviram, M., Hussein, O., Rosenblat, M., Schlezinger S., Hayek T. (1998) Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J. Cardiovasc. Pharmacol. 31, 39-45.
62. Giroux, L. M., Davignon, J., and Naruszewicz, M. (1993) Simvastatin inhibits the oxidation of low density lipoproteins by activated human monocyte-derived macrophages. Biochim. Biophys. Acta. 1165, 335-338.
63. Sanchez-Quesada, J. L., Otal-Entraigas, C., Franco, M., Jorba O., González-Sastre F. (1999) Effect of simvastatin treatment on the electronegative low density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 84, 655-659.
64. Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks F. M., Moye L. A., et al. (1998) for the cholesterol and recurrent events (CARE) investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98, 839-844.
65. Lindahl, B., Toss, H., Siegbahn, A., Venge P., Wallentin L. (2000) Markers of myocardial damage and inflammation in relation to long term mortality in unstable coronary artery disease. N. Engl. J. Med. 343, 1139-1147.
66. Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks F., Braunwald E., for the Cholesterol and Recurrent Events (CARE) Investigators. (1999) Long term effects of pravastatin on plasma concentration of C reactive protein. Circulation 100, 230-235.
67. Albert, M. A., Danielson, E., Rifai, N., Ridker P. M., PRINCE Investigators. (2001) Effect of statin therapy on C reactive protein levels-the prasavtatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286, 64-70.
68. Van Wissen, S., Trip, M. D., Snilde, T. J., de Graaf J., Stalenhoef A. F., Kastelein J. J. (2002) Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 165, 361-366.
69. Plenge, J. K., Hernandez, T. L., Weil, K. M., Poirier P., Grunwald G. K., et al. (2002) Simvastatin lowers C reactive protein within 14 days: an effect independent of low density lipoprotein cholesterol reduction. Circulation 106, 1447-1452.
70. Olsson, A. G. and Schwartz, G. G. (2002) Early initiation of treatment with statins in acute coronary syndromes. Ann. Med. 34, 37-41.
71. Bellosta, S., Via, D., Canavesi, M., Pfister P., Fumagalli R., et al. (1998) HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. 18, 1671-1678.
72. Crisby, M., Nordin-Fredriksson, G., Shah, P. K., Yano J., Zhu J., Nilsson J. (2001) Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103, 926-933.
73. Suwaidi, J. A., Hamaski, S., Higano, S. T., Nishimura, R. A., Holmes, D. R., Jr. et al. (2000) Long term follow up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101, 948-954.
74. Schachinger, V., Britten, M. B., and Zeiher, A. M. (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long term outcome of coronary heart disease. Circulation 101, 1899-1906.
75. Perticone, F., Ceravolo, R., Pujia, A., Ventura G, Iacopino S, et al. (2001) Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104, 191-196.
76. Gokce, N., Keaney, J. F., Jr., Hynter, L. M., Watkins M. T., Menzoian J. O., Vita J. A. (2002) Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 105, 1567-1572.
77. Halcox, J. P. J., Schenke, W. H., Zalos, G., Mincemoyer R., Prasad A., et al. (2002) Prognostic value of coronary vascular endothelial dysfunction. Circulation 106, 653-658.
78. Hill, J., Zalos, G., Halcox, J. P. J., Schenke W. H., Waclawiw M. A., et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348, 593-600.
79. Llevadot, J., Murasawa, S., Kureishi, Y., Uchida S., Masuda H., et al. (2001) HMG-CoA reductase inhibitor mobilizes bone marrow derived endothelial progenitor cells. J. Clin. Invest. 108, 399-405.
80. Dimmeler, S., Aicher, A., Vasa, M., Mildner-Rihm C., Adler K. (2001) HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108, 391-397.
81. Vasa, M., Fichtlscherer, S., Adler, K., Aicher A., Martin H., et al. (2001) Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103, 2885-2890.
82. Landmesser, U., Engberding, N., Bahlmann, F. H., Schaefer A., Wiencke A., et al. (2004) Statin induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110, 1933-1939.
83. Asahara, T., Masuda, H., Takahashi, T., Kalka C., Pastore C. (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85, 221-228.
84. Kawamoto, A., Gwon, H. C., Iwaguro, H., Yamaguchi J. I., Uchida S., et al. (2001) Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103, 634-637.
85. Kocher, A. A., Schuster, M. D., Szabolcs, M. J., Takuma S., Burkhoff D., et al. (2001) Neovascularization of ischemic myocardium by human bone-marrow derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7, 430-436.
86. Aicher, A., Heeschen, C., Mildner-Rihm, C., Urbich C, Ihling C., (2003) Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9, 1370-1376.
87. Walter, D. H., Ritting, K., Bahlmann, F. H., Kirchmair R., Silver M., et al. (2002) Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow derived endothelial progenitor cells. Circulation 105, 3017-3024.
88. Matsunaga, T., Weihrauch, D. W., Moniz, M. C., Tessmer J., Warltier D. C., Chilian W. M. (2002) Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. Circulation 105, 2185-2191.
89. Sobrino, T., Blanco, M., Perez-Mato, M., Rodriguez-Yanez, M., and Castillo, J. (2012) Increased levels of circulating endothelial progenitor cells in patients with ischemic stroke treated with statins during acute phase. Eur. J. Neurol. 19, 1539-1546.
90. Paradisi, G., Bracaglia, M., Basile, F., Di'Ipolito S., Di Nicuolo F., et al. (2012) Effect of pravastatin on endothelial function and endothelial progenitor cells in healthy postmenopausal women. Clin. Exp. Obstet. Gynecol. 39, 153-159.
91. Baran, C., Durdu, S., Dalva, K., Zaim Ç., Dogan A., et al. (2012) Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: a randomized, controlled trial. Stem Cell Rev. Rep. 8, 963-971.
92. Iwakura, A., Luedemann, C., Shastry, S., Hanley A., Kearney M. (2003) Estrogen mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 108, 3115-3121.
93. Koh, K. K., Schenke, W. H., Waclawiw, M. A., Csako, G., and Cannon, R. O., III. (2002) Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation 105, 1531-1533.
94. Zanger, D., Yang, B. K., Ardans, J., Waclawiw, M. A., and Csako, G., et al. (2000) Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J. Am. Coll. Cardiol. 36, 1797-1802.
95. Laufs, U., Werner, N., Link, A., et al. (2004) Physical training increases endothelial progenitor cells. Inhibits neointima formation, and enhances angiogenesis. Circulation 109, 220-226.
96. Desai, A., Glaser, A., Liu, D., Endres M., Wassmann S., et al. (2009) Microarray-based characterization of a colony assay used to investigate endothelial progenitor cells and relevance to endothelial function in humans. Arterioscler. Thromb. Vasc. Biol. 29, 121-127.
97. Liu, D., Glaser, A. P., Patibandla, S., Blum A., Munson P. J., et al. (2011) Transcriptional profiling of CD133+ cells in coronary artery disease and effects of exercise on gene expression. Cytotherapy 13, 227-236.
98. Song, L., Yang, Y. J., Dong, Q. T., Qian H. Y., Gao R. L., et al. (2013) Atorvastatin enhance efficacy of mesenchymal stem cells treatment for swine myocardial infarction via activation of nitric oxide syntase. PLoS One 8, e65702.
99. Sukpat, S., Isarasena, N., Wongphoom, J., Patumraj, S. (2013) Vasculoprotective effects of combined endothelial progenitor cells and mesenchymal stem cells in diabetic wound care: their potential role in decreasing wound oxidative stress. BioMed Res. Int. 2013, 8. doi.org/10.1155/2013/459196.
100. Hare, J. M., Blum, A., and Heldman, A. W. (2013) Cardiac cell based therapy: methods of application and delivery systems. In Cardiac Catheterization, Angiography, and Intervention, 8th edn. (Grossman B and Baim D). pp. 871-889. Lippincott, Williams & Wilkins, Philadelphia PA 19103 USA.